Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CoreValve predicts 2007 EU approval for percutaneous heart valve technology

This article was originally published in Clinica

Executive Summary

French firm CoreValve believes it could be set to gain European market approval next year for its percutaneous heart valve replacement technology, the ReValving system. The company recently began a 100-patient clinical trial of a third-generation version of the product, which comprises a delivery catheter component that has been reduced in size to 18F. The first-generation system featured a 25F catheter, which is "very sizeable" by interventional standards, explained the Paris-based firm. As well as the delivery catheter, CoreValve's product consists of a porcine pericardium valve that is mounted on a self-expanding stent. The device is delivered using standard "cath lab" techniques.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT051824

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel